Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Scam alert: Beware of emails impersonating MOH that request for a mandatory “Digital Health Verification”.


MOH does not own this portal and will only request verification via official channels. If in doubt, call the MOH hotline at 6325 9220 to verify the email’s authenticity.

Ministry of Health
Parliamentary QA

SUSTAINABILITY OF RARE DISEASE FUND AND AVAILABILITY OF DONOR-AUTHORISED PRINCIPAL FOR CELL, TISSUE AND GENE THERAPY PRODUCTS

6 October 2026

NOTICE PAPER NO. 1392

NOTICE OF QUESTION FOR WRITTEN ANSWER

FOR THE SITTING OF PARLIAMENT ON 6 OCTOBER 2026


Name and Constituency of Member of Parliament

Mr Low Wu Yang Andre

Non-Constituency MP


Question No. 2190

To ask the Coordinating Minister for Social Policies and Minister for Health (a) what were the Rare Disease Fund’s fund size, investment income, donations and expenditure for each of FY2023 to FY2025; (b) how many patient applications were received, approved, rejected or pending in each year; and (c) what donor-authorised principal is presently available for drawn down of donation for Cell, Tissue and Gene Therapy Products.

Answer

1 As at end-FY2025, RDF’s fund size is $187 million – $155 million is held in endowment and $32 million is an expendable amount to support patients.

2 Given that the number of applications is not big and fluctuates from year-to-year, we have provided aggregate figures for FY2023 to FY2025. Over this period, the RDF received $4.9 million in donations, $15.6 million in Government matching grants and $1.4m in realized investment income; seven applications were received and six were approved. $3.4 million was used to support 14 patients.

3 RDF was extended to support Cell, Tissue and Gene Therapy Products (CTGTP) treatments in 2023. Following this recent expansion, about $4 million is currently available to support applications from patients requiring CTGTP treatments.